Increased uptake of immune checkpoint inhibitors drives growth

The global market for cancer immunotherapies currently tops $33bn in value, with Celgene, Bristol-Myers Squibb and Roche amongst the key players. The market is anticipated to exceed $103.4bn in sales by 2024 at a compound annual growth rate (CAGR) of 17.4%, according to GBI Research.

cancer immunotherapies pipeline moleculeGBI Research’s newly published report ‘Global Cancer Immunotherapies Market to 2024 – Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline’ covers all cancer immunotherapies, focusing in particular on five key indications – breast cancer, leukemia, lymphoma, melanoma and non-small cell lung cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cancer immunotherapies comprise a highly active therapy area with 3,863 drugs in active development, representing around half of the overall oncology pipeline. Despite being a strong pipeline, approximately 62% of the pipeline is made up of early stage products.

Mark Needham, analyst at GBI Research, comments: “There is strong interest from pharmaceutical companies to develop cancer immunotherapies, as demonstrated by the large number of companies active within the therapy area. The large proportion of early stage products may partly be attributed to an increase in activity in recent years.

“Many of the top-selling drugs are approved for the treatment of multiple types of cancer, which is driving competition.”

Highlights of the report include:

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
  • Assessment of the current treatment landscape
  • Analysis of the pipeline and clinical trial landscapes, including trends for stage of development, key indication, molecule type and molecular target
  • Multi-scenario forecast predictions for market growth, including segmentation for premium and generic products, key companies and key drug classes

GBI Research’s latest report will help you to see the impact that various new approvals and late-stage products will have on the market, and predict market size growth, with in-depth forecasting from 2017 to 2024.

If you would like any more information on this report, please visit the GBI Research Report Store.